Otonomy Enrolls First Meniere’s Disease Patients in OTO-104 Multiple-Dose Safety Study

SAN DIEGO, Oct. 9, 2014 (GLOBE NEWSWIRE) Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the enrollment of the first patients in a multiple-dose safety study of OTO-104 initiated in the United Kingdom (U.K.) in patients with Ménière’s disease.

Read More

Otonomy Added To Russell 2000(R) Index

SAN DIEGO, Oct. 1, 2014 (GLOBE NEWSWIRE) Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that the company was added to the Russell 2000® Index as part of Russell Investments’ quarterly addition of select initial public offering (IPO) companies.

Read More

Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases

Chief Medical Officer Appointed to Advance Growing Portfolio; Series A Extension Earmarked for Second Product Candidate Preclinical Development

San Carlos, CA – September 30, 2014 Allakos Inc. announced today that it has secured an additional $10 million investment from current investors to fund development of an additional therapeutic antibody.

Read More

ZS Pharma Announces Positive Top-Line Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia

ZS-9 meets primary endpoint at all three doses tested

Coppell, Texas – September 23, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced positive top-line results from HARMONIZE (ZS004), its second Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate), a novel investigational treatment for hyperkalemia.

Read More